Gattex teduglutide: Completed Phase III enrollment

NPS completed enrollment and randomization of 86 patients in the double-blind, placebo-controlled, international Phase III STEPS trial to evaluate daily 0.05 mg/kg doses of subcutaneous Gattex for 24 ...